Uncertainty around the event and suspected tax changes in the upcoming budget has left many investors in the dark.

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future ...

The summit comes amid a rocky first 100 days in government, marked by resignations and a scandal over ‘freebies’ for the ...

Stellantis CEO Carlos Tavares on Monday declined to rule out job cuts and said keeping up with Chinese competition and ...

DNA submitted by users to the genealogy company 23andMe will remain private for now, with CEO Anne Wojcicki saying she no ...

GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of the heartburn drug Zantac caused cancer, the company announced on ...

EasyJet has hired Jan De Raeymaeker as its finance chief from European rail freight operator Lineas, replacing Kenton Jarvis ...

British Prime Minister Keir Starmer kicked off an international business investment summit aimed at pulling in billions of ...

Dr. Baldoni’s career includes 29 years in R&D at GSK, where he served as Senior Vice President of ... "We are pleased to welcome Dr. Baldoni to our Scientific Advisory Board," said Vin Singh, CEO of ...

(Alliance News) - GSK PLC on Wednesday announced that the US Food & Drug Administration has accepted its New Drug Application for gepotidacin. The London-based biopharma company said the FDA has ...

Starmer promised of the Labour government that “Our door is open,” when the corporations are in fact already inside dictating ...

GSK has reached agreements with 10 plaintiff firms to settle around 80,000 state court product liability cases related to its heartburn medication, Zantac, for $2.2 billion.